ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc (SNDX)

17.93
-0.34
(-1.86%)
Closed September 23 4:00PM
17.93
-0.01
(-0.06%)
After Hours: 7:22PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
17.93
Bid
17.66
Ask
19.02
Volume
937,684
17.86 Day's Range 18.57
11.215 52 Week Range 25.34
Market Cap
Previous Close
18.27
Open
18.38
Last Trade Time
Financial Volume
$ 17,037,994
VWAP
18.1703
Average Volume (3m)
1,017,013
Shares Outstanding
85,096,358
Dividend Yield
-
PE Ratio
-7.29
Earnings Per Share (EPS)
-2.46
Revenue
-
Net Profit
-209.36M

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and ... Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Syndax Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SNDX. The last closing price for Syndax Pharmaceuticals was $18.27. Over the last year, Syndax Pharmaceuticals shares have traded in a share price range of $ 11.215 to $ 25.34.

Syndax Pharmaceuticals currently has 85,096,358 shares outstanding. The market capitalization of Syndax Pharmaceuticals is $1.55 billion. Syndax Pharmaceuticals has a price to earnings ratio (PE ratio) of -7.29.

SNDX Latest News

Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvoโ„ข (axatilimab-csfr) in Chronic Graft-Versus-Host Disease

Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvoโ„ข (axatilimab-csfr) in Chronic Graft-Versus-Host Disease PR...

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., Sept. 6, 2024 WALTHAM, Mass., Sept. 6, 2024 /PRNewswire/ -- Syndax...

Incyte und Syndax melden FDA-Zulassung von Niktimvoโ„ข (Axatilimab-csfr) zur Behandlung der chronischen Graft-versus-Host-Krankheit (GvHD)

Niktimvoโ„ข (Axatilimab-csfr) ist der erste zugelassene Anti-CSF-1R-Antikรถrper, der auf die Ursachen von Entzรผndung und Fibrose bei chronischer GvHD abzielt Daten der AGAVE-201-Studie, die die...

Incyte et Syndax annoncent lโ€™approbation par la FDA amรฉricaine de Niktimvoโ„ข (axatilimab-csfr) pour le traitement de la maladie chronique du greffon contre lโ€™hรดte (GVHD)

Niktimvoโ„ข (axatilimab-csfr) est le premier anticorps anti-CSF-1R autorisรฉ ร  cibler les moteurs de lโ€™inflammation et de la fibrose observรฉs dans la GVHD chronique Les donnรฉes clรฉs de lโ€™รฉtude...

Incyte and Syndax Announce U.S. FDA Approval of Niktimvoโ„ข (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Niktimvoโ„ข (axatilimab-csfr) is the first approved anti-CSF-1R antibody targeting the drivers of inflammation and fibrosis seen in chronic GVHD Pivotal data from the AGAVE-201 study supporting...

Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia

Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia PR Newswire WALTHAM, Mass...

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., Aug. 5, 2024 WALTHAM, Mass., Aug. 5, 2024 /PRNewswire/ -- Syndax...

Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update

Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update PR Newswire WALTHAM, Mass., Aug. 1, 2024 โ€“ย  Axatilimab BLA in refractory chronic GVHD is under...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.21-6.3218390804619.1419.1417.34150469718.25380244CS
4-2.77-13.381642512120.721.5617.34113113218.92697018CS
12-2.46-12.064737616520.3925.0717.34101701320.75201071CS
26-4.65-20.59344552722.5825.0717.34103303720.84656074CS
522.0412.838263058515.8925.3411.215137005118.78795223CS
156-0.91-4.8301486199618.8429.8611.21593307519.73180055CS
2609.23106.0919540238.729.865.3576709719.18869312CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAVLKaival Brands Innovations Group Inc
$ 1.33
(129.71%)
182.46M
LASELaser Photonics Corporation
$ 18.8671
(81.24%)
13.54M
TGLTreasure Global Inc
$ 1.18
(73.45%)
139.95M
NVVENuvve Holding Corporation
$ 6.68
(70.41%)
31.34M
UXINUxin Ltd
$ 2.42
(52.68%)
18.24M
ELABElevai Labs Inc
$ 0.10545
(-62.34%)
23.66M
ADTXAditxt Inc
$ 0.262
(-31.52%)
3.17M
FRGTFreight Technologies Inc
$ 0.081
(-28.82%)
26.35M
ANEBAnebulo Pharmaceuticals Inc
$ 2.23
(-27.60%)
113.78k
STSSSharps Technology Inc
$ 0.1722
(-27.06%)
2.27M
XPONExpion360 Inc
$ 0.1144
(34.91%)
432.17M
NVDANVIDIA Corporation
$ 116.26
(0.22%)
206.23M
INTCIntel Corporation
$ 22.56
(3.30%)
184.44M
KAVLKaival Brands Innovations Group Inc
$ 1.33
(129.71%)
182.46M
TGLTreasure Global Inc
$ 1.18
(73.45%)
139.95M

SNDX Discussion

View Posts
dinogreeves dinogreeves 1 week ago
Have you looked at TIL on Friday.
๐Ÿ‘๏ธ0
Monksdream Monksdream 1 week ago
SNDX a buy again
๐Ÿ‘๏ธ0
dinogreeves dinogreeves 12 months ago
SNDX had the highest volume today for some reason, this is either going to tank hard on Monday or hit 30...50....60 dollars. Took my chances with 600 shares.
๐Ÿ‘๏ธ0
dinogreeves dinogreeves 12 months ago
Possibly a huge run on Monday, very possible or they missed the trial. Huge 400 million in the coffers and monster institutional ownership.
๐Ÿ‘๏ธ0
dealerschool2006 dealerschool2006 3 years ago
Nice rebound today for $SNDX, beat the street and conference call was successful!!!
๐Ÿ‘๏ธ0
dealerschool2006 dealerschool2006 3 years ago
SNDX recovering from panic sale!!!
๐Ÿ‘๏ธ0
dealerschool2006 dealerschool2006 3 years ago
Panic sale for SNDX on positive results...May options wide swings...
๐Ÿ‘๏ธ0
DaytraderJohn DaytraderJohn 4 years ago
Its interesting how a company such as this can go on to have revenue loss of 50m+ per year. Yet still give higher ups 200k+ cash bonuses and large salaries.

They have no product revenue.

I expect shares to be diluted after earnings.

Read their 10k. I guess it's a gamble play incase one day they do get approval.
๐Ÿ‘๏ธ0
BoilerRoom BoilerRoom 5 years ago
$SNDX looks like this run is going to continue. Letโ€™s hit $15.00 this week folks
๐Ÿ‘๏ธ0
ClayTrader ClayTrader 5 years ago
* * $SNDX Video Chart 01-31-2020 * *

Link to Video - click here to watch the technical chart video

๐Ÿ‘๏ธ0
BoilerRoom BoilerRoom 5 years ago
$SNDX next week is going to be fun
๐Ÿ‘๏ธ0
BoilerRoom BoilerRoom 5 years ago
$SNDX Hope you guys went all in here...Have a great weekend see yโ€™all on Monday
๐Ÿ‘๏ธ0
BoilerRoom BoilerRoom 5 years ago
$SNDX holding this baby!
๐Ÿ‘๏ธ0
BoilerRoom BoilerRoom 5 years ago
$SNDX keep climbing baby! Going be going up all next week
๐Ÿ‘๏ธ0
BoilerRoom BoilerRoom 5 years ago
$SNDX looking awesome from my call at $8.00
๐Ÿ‘๏ธ0
BoilerRoom BoilerRoom 5 years ago
$SNDX got us a runner folks!!!
๐Ÿ‘๏ธ0
BoilerRoom BoilerRoom 5 years ago
$SNDX Chomp Chomp Chomp!
๐Ÿ‘๏ธ0
BoilerRoom BoilerRoom 5 years ago
$SNDX Weeeeeeeeeee
๐Ÿ‘๏ธ0
BoilerRoom BoilerRoom 5 years ago
Going to run folks.
๐Ÿ‘๏ธ0
BoilerRoom BoilerRoom 5 years ago
$SNDX in at $8.00
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 5 years ago
News News Alert: Syndax Announces $35.0 Million Offering of Common Stock...
๐Ÿ‘๏ธ0
whytestocks whytestocks 5 years ago
News: $SNDX Syndax Announces $26.2 Million Offering of Common Stock and Warrants

WALTHAM, Mass. , March 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement with Biotechnolo...

Find out more https://marketwirenews.com/news-releases/syndax-announces-26-2-million-offering-of-common-stock-and-warrants-7897910.html
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
SNDX 3Q18 resultsโ€”cash=$89.6M:

https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-third-quarter-2018-financial-results-and-provides-clinical-and-business-update-300744153.html
๐Ÿ‘๏ธ0
Spartak Spartak 6 years ago
Well, the company is done. What a disaster.
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
SNDX -21%/AH on PFS failure in HR+/HER2- breast cancer:

https://finance.yahoo.com/news/syndax-host-conference-call-phase-200500374.html

The trial continues to test for statsig OS every six months until Nov 2019.
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
SNDX -20% on no newsโ€”sell-off could be related to recent general bearishness for PD-(L1) add-on agents, which was a theme at ESMO.
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
SNDX upgrades BoD:

https://www.prnewswire.com/news-releases/syndax-announces-changes-to-its-board-of-directors-300718661.html
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
#msg-143766395
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
SNDX phase-3 PFS data now expected in 4Q18 (rather than 3Q18); I essentially called this back in May (#msg-140923103, bottom):

https://www.prnewswire.com/news-releases/syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-pembrolizumab-in-non-small-cell-lung-cancer-300717717.html
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
#msg-143642544
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
SNDX 2Q18 CC transcript:

https://finance.yahoo.com/news/edited-transcript-sndx-earnings-conference-152734163.html
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
SNDX 2Q18 itemsโ€”6/30/18 cash=$98.4Mโ€ฆ

PR:
http://ir.syndax.com/news-releases/news-release-details/syndax-pharmaceuticals-reports-second-quarter-2018-financial

CC slides:
http://ir.syndax.com/static-files/18eaf63a-6c93-45cd-8272-60479300c153
๐Ÿ‘๏ธ0
Spartak Spartak 6 years ago
When does pounding stop? Someone hummers it pretty badly.
๐Ÿ‘๏ธ0
fsantes fsantes 6 years ago
Ill keep a look out for some then!... Iโ€™ve been looking as well. Thank you!
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
No. I generally post anything that's material.
๐Ÿ‘๏ธ0
fsantes fsantes 6 years ago
Have you heard any new news on SNDX?
๐Ÿ‘๏ธ0
fsantes fsantes 6 years ago
I really appreciate it. Bought some shares as one advisor mentioned it to me but keeping track of whatโ€™s going on on it
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
SNDX requested that the SEC keep this document in redacted form:

https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/sndx-ex101_169.htm

This was filed as an exhibit to the most recent 10-Q.
๐Ÿ‘๏ธ0
fsantes fsantes 6 years ago
Do you know whatโ€™s the news that came out about? When I look itโ€™s blank..
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
SNDX, NKTR ink clinical-trial collaboration for Entinostat + NK-214 in second-lime melanoma:

https://www.prnewswire.com/news-releases/syndax-and-nektar-therapeutics-announce-immuno-oncology-clinical-trial-collaboration-300656793.html

NKTR is furnishing free drug for the phase-1/2 clinical trial, but no cash.
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
SNDX ENCORE-601 updateโ€ฆ

PR:
https://www.prnewswire.com/news-releases/syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-pembrolizumab-300650233.html

CC slides:
http://ir.syndax.com/static-files/7c0c8627-0b81-43d6-9210-6cb02684db5f
๐Ÿ‘๏ธ0
tika1 tika1 6 years ago
After failure of two high profile IO combination, I think SNDX will go nowhere for its own IO combo.

All eyes on Etinostat + exemestane only. Still chance of double, if that turns out good.
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
Transcript of SNDX 1Q18 CC:

https://finance.yahoo.com/news/edited-transcript-sndx-earnings-conference-235620976.html
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
SNDX new investor slide set:

http://ir.syndax.com/static-files/da19e99b-2bd2-4456-91fe-0e67b97fc0d0
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
The 1Q18 10-Q has been filed:

https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/sndx-10q_20180331.htm
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
SNDX 1Q18 resultsโ€”cash=$113M:

https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-first-quarter-2018-financial-results-and-provides-clinical-and-business-update-300644832.html
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
SNDX ASCO lineup:

https://finance.yahoo.com/news/syndax-pharmaceuticals-announces-presentations-2018-200500073.html
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
Yesโ€”please see my reply in #msg-140012720.
๐Ÿ‘๏ธ0
tika1 tika1 6 years ago
Dew,
Is there any hope for success of this trial after high profile INCY failure? What is your take on SNDX current weakness?


Oral Presentations:

Title: Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - results from SNDX-275-0141 phase I trial
Presenter: Anthony W. Tolcher, M.D.
Category: Clinical Trials
Session: Biomarkers in Immuno-oncology
Abstract Number: CT179
Location: N Hall C - McCormick Place North (Level 1)
Date and Time: Tuesday April 17, 2018; 3:50 PM - 4:05 PM C.T.
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
SNDX presentation lineup at AACR:

https://finance.yahoo.com/news/syndax-present-2018-american-association-110000742.html
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock